At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 332 enrolled
Drug / intervention
Farletuzumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Farletuzumab and Placebo for Platinum-Sensitive Ovarian Cancer in First Relapse. Completed, enrolled 332 participants across 68 sites in 7 countries.
Detailed Summary
MORAb-003-011 is a global, multicenter, double-blind, randomized placebo-controlled study to assess the safety and efficacy of farletuzumab in combination with standard chemotherapy in subjects with low cancer antigen 125 (CA125) platinum-sensitive ovarian cancer in first relapse.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Germany, Italy, Japan, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartMar 2015
Primary CompletionMay 2019
Study CompletionAug 2020
TodayJul 2026
First PostedNov 13, 2014
Enrollment StartMar 19, 2015
Primary CompletionMay 31, 2019
Study CompletionAug 13, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.6 years ago
Interventions
Farletuzumabdrug
Farletuzumab will be administered intravenously (IV) weekly
Placebodrug
Placebo will be administered intravenously (IV) weekly